Source:

Special Report: Ideologically, Where Is the U.S. Moving?
| D | L | Ma | Me | J | V | S |
|---|---|---|---|---|---|---|
| « juin | août » | |||||
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 | |
Source:

Special Report: Ideologically, Where Is the U.S. Moving?
La semaine dernière, l'organisation écologique NEF (New Economics Foundation) a publié une étude détaillant l'empreinte écologique de chaque pays c.-à-d. le nombre de planètes Terre qui est nécessaire pour supporter le niveau de vie des citoyens d'un pays. Cette étude visait bien entendu à nous convaincre que nous devons changer notre mode de vie parce que nous exploitons la planète de manière non soutenable.
Par contre, les auteurs de l'étude sont rapidement passés sur les statistiques qui dépeignent leur concept de développement durable sous un jour assez sombre…

Une vie insoutenable pour avoir un développement durable… J'ai de la difficulté à concevoir comment on peut considérer ce projet comme un progrès ou un idéal à atteindre.

P.-S. Selon les auteurs de l'étude, les Cubains arrivent à la 7e position des pays les plus heureux alors que les Américains sont relégués à la 150e position. Étrange, aux dernières nouvelles ce sont les Cubains qui essayent d'aller vivre aux États-Unis et pas l'inverse.
Source:

The Happy Planet Index
|
- |
Grant System Leads Cancer Researchers to Play It Safe The fight against cancer is going slower than most had hoped, with only small changes in the death rate in the almost 40 years since it began. One major impediment, scientists agree, is the grant system itself. It has become a sort of jobs program, a way to keep research laboratories going year after year with the understanding that the focus will be on small projects unlikely to take significant steps toward curing cancer. In fact, it has become lore among cancer researchers that some game-changing discoveries involved projects deemed too unlikely to succeed and were therefore denied federal grants, forcing researchers to struggle mightily to continue. Take one transformative drug, for breast cancer. It was based on a discovery by Dr. Dennis Slamon of the University of California, Los Angeles, that very aggressive breast cancers often have multiple copies of a particular protein, HER-2. That led to the development of herceptin, which blocks HER-2. Now women with excess HER-2 proteins, who once had the worst breast cancer prognoses, have prognoses that are among the best. But when Dr. Slamon wanted to start this research, his grant was turned down. He succeeded only after the grateful wife of a patient helped him get money from Revlon, the cosmetics company. |
